Loading patent…
AssigneeLaboratorios Salvat, S.A.
InventorsXavier CAPDEVILA NORTES, Javier SANAGUSTIN AQUILUE, Maria Isabel DELGADO GANAN
Estimating the term…
The invention relates to a new therapeutic approach for treatment and/or prevention of a disease of the posterior segment of the eye, in particular for retinal and optic nerve pathologies. Dobesilic acid and/or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, are proposed for use topically administered onto eye surface. There are also disclosed new compositions comprising dobesilic acid and/or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, adapted for performing the treatment and/or prevention of diseases of the posterior segment of the eye.
A method for the treatment or prevention of a disease of the posterior segment of the eye, comprising topically administering onto eye surface a therapeutically effective amount of dobesilic acid or an ester thereof, or a pharmaceutically acceptable salt of the dobesilic acid or dobesilic acid ester in a subject in need thereof, including a human, wherein the treatment comprises administration of a topical dose of the dobesilic acid or ester thereof, or the pharmaceutically acceptable salt of the dobesilic acid or dobesilic acid ester, from 0.01 mg/day to 400 mg/day.
(canceled)
(canceled)
(canceled)
(canceled)
A method for the treatment or prevention of a disease of the posterior segment of the eye, comprising topically administering onto eye surface, a pharmaceutical topical eye composition that comprises a therapeutically effective amount of dobesilic acid, or an ester thereof, or a pharmaceutically acceptable salt of the dobesilic acid or dobesilic acid ester, together with one or more pharmaceutically acceptable topical excipients or carriers in a subject in need thereof, including a human;
(canceled)
Dependencies are inferred from the claim text.